Celadon Pharmaceuticals Plc announced the results of an early economic analysis of the data collected as part of the feasibility study for its fully approved chronic pain clinical trial. The analysis was undertaken by York Health Economic Consulting which provides consultancy and research services in health economics. The findings of YHEC's analysis are as follows: Patients on the feasibility study recorded an almost 50% (49.6%) reduction in pain scores in the first month of using cannabis-based medicines, with this reduction in pain being sustained throughout the three-month study.

Patients saw a significant improvement in their mean quality of sleep scores of 1.6 points (p=0.01) and a reduction in the use of opioids and associated medicines. When assessed using the economic framework recommended by NICE, adding cannabis-based medicines to the Standard of Care was found to deliver a cost-effective solution and, depending on the price point, a cost saving to the National Health Service and Patients' quality-adjusted life years also increased.